▶ 調査レポート

副腎白質ジストロフィー治療薬の世界市場 2020年

• 英文タイトル:Global Adrenoleukodystrophy Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。副腎白質ジストロフィー治療薬の世界市場 2020年 / Global Adrenoleukodystrophy Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 / GIR201100253資料のイメージです。• レポートコード:GIR201100253
• 出版社/出版日:GlobalInfoResearch / 2020年10月20日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、102ページ
• 納品方法:Eメール
• 産業分類:医薬品・医療
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本書では、副腎白質ジストロフィー治療薬の世界市場を調査対象にし、副腎白質ジストロフィー治療薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析(北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ)、種類別分析(ビオチン、DRX-065、DUOC-01、Lenti-D、MIN-102、OP-101、その他)、用途別分析(子供、大人)、市場予測(2021年~2025年)、販売チャンネル・代理店分析情報などを整理しました。
・市場概要
・メーカー情報:Applied Genetic Technologies Corp、Viking Therapeutics Inc、Minoryx Therapeutics sl、Bluebird Bio Inc、SOM Biotech SL、MedDay SA、ReceptoPharm Inc、Pfizer Inc
・メーカー別販売量、売上、市場シェア
・副腎白質ジストロフィー治療薬の地域別市場分析
・副腎白質ジストロフィー治療薬の北米市場規模2015-2020:アメリカ、カナダ、メキシコ
・副腎白質ジストロフィー治療薬のヨーロッパ市場規模2015-2020:ドイツ、イギリス、フランス、ロシアなど
・副腎白質ジストロフィー治療薬のアジア市場規模2015-2020:日本、中国、韓国、インド、東南アジアなど
・副腎白質ジストロフィー治療薬の南米市場規模2015-2020:ブラジル、アルゼンチンなど
・副腎白質ジストロフィー治療薬の中東・アフリカ市場規模2015-2020:サウジアラビア、トルコ、エジプト、南アフリカなど
・副腎白質ジストロフィー治療薬の種類別市場規模2015-2020:ビオチン、DRX-065、DUOC-01、Lenti-D、MIN-102、OP-101、その他
・副腎白質ジストロフィー治療薬の用途別市場規模2015-2020:子供、大人
・副腎白質ジストロフィー治療薬の世界市場予測2021-2025:地域別、種類別、用途別
・販売チャンネル・代理店分析
・調査の結果・結論

Market Overview
The global Adrenoleukodystrophy Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Adrenoleukodystrophy Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Adrenoleukodystrophy Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Adrenoleukodystrophy Drugs market has been segmented into
Biotin
DRX-065
DUOC-01
Lenti-D
MIN-102
OP-101
Others

By Application, Adrenoleukodystrophy Drugs has been segmented into:
Children
Adult

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Adrenoleukodystrophy Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Adrenoleukodystrophy Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Adrenoleukodystrophy Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Adrenoleukodystrophy Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Adrenoleukodystrophy Drugs Market Share Analysis
Adrenoleukodystrophy Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Adrenoleukodystrophy Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Adrenoleukodystrophy Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Adrenoleukodystrophy Drugs are:
Applied Genetic Technologies Corp
Viking Therapeutics Inc
Minoryx Therapeutics sl
Bluebird Bio Inc
SOM Biotech SL
MedDay SA
ReceptoPharm Inc
Pfizer Inc

Among other players domestic and global, Adrenoleukodystrophy Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adrenoleukodystrophy Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Adrenoleukodystrophy Drugs, with price, sales, revenue and global market share of Adrenoleukodystrophy Drugs in 2018 and 2019.
Chapter 3, the Adrenoleukodystrophy Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adrenoleukodystrophy Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Adrenoleukodystrophy Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Adrenoleukodystrophy Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

Table of Contents

1 Market Overview
1.1 Adrenoleukodystrophy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Adrenoleukodystrophy Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Biotin
1.2.3 DRX-065
1.2.4 DUOC-01
1.2.5 Lenti-D
1.2.6 MIN-102
1.2.7 OP-101
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Adrenoleukodystrophy Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Children
1.3.3 Adult
1.4 Overview of Global Adrenoleukodystrophy Drugs Market
1.4.1 Global Adrenoleukodystrophy Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Applied Genetic Technologies Corp
2.1.1 Applied Genetic Technologies Corp Details
2.1.2 Applied Genetic Technologies Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Applied Genetic Technologies Corp SWOT Analysis
2.1.4 Applied Genetic Technologies Corp Product and Services
2.1.5 Applied Genetic Technologies Corp Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Viking Therapeutics Inc
2.2.1 Viking Therapeutics Inc Details
2.2.2 Viking Therapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Viking Therapeutics Inc SWOT Analysis
2.2.4 Viking Therapeutics Inc Product and Services
2.2.5 Viking Therapeutics Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Minoryx Therapeutics sl
2.3.1 Minoryx Therapeutics sl Details
2.3.2 Minoryx Therapeutics sl Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Minoryx Therapeutics sl SWOT Analysis
2.3.4 Minoryx Therapeutics sl Product and Services
2.3.5 Minoryx Therapeutics sl Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bluebird Bio Inc
2.4.1 Bluebird Bio Inc Details
2.4.2 Bluebird Bio Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Bluebird Bio Inc SWOT Analysis
2.4.4 Bluebird Bio Inc Product and Services
2.4.5 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 SOM Biotech SL
2.5.1 SOM Biotech SL Details
2.5.2 SOM Biotech SL Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 SOM Biotech SL SWOT Analysis
2.5.4 SOM Biotech SL Product and Services
2.5.5 SOM Biotech SL Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 MedDay SA
2.6.1 MedDay SA Details
2.6.2 MedDay SA Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 MedDay SA SWOT Analysis
2.6.4 MedDay SA Product and Services
2.6.5 MedDay SA Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 ReceptoPharm Inc
2.7.1 ReceptoPharm Inc Details
2.7.2 ReceptoPharm Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 ReceptoPharm Inc SWOT Analysis
2.7.4 ReceptoPharm Inc Product and Services
2.7.5 ReceptoPharm Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Pfizer Inc
2.8.1 Pfizer Inc Details
2.8.2 Pfizer Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Pfizer Inc SWOT Analysis
2.8.4 Pfizer Inc Product and Services
2.8.5 Pfizer Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Adrenoleukodystrophy Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Adrenoleukodystrophy Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Adrenoleukodystrophy Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Adrenoleukodystrophy Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Adrenoleukodystrophy Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Adrenoleukodystrophy Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Adrenoleukodystrophy Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
4.5 South America Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Adrenoleukodystrophy Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Adrenoleukodystrophy Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Adrenoleukodystrophy Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Adrenoleukodystrophy Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Adrenoleukodystrophy Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Adrenoleukodystrophy Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
6.3 UK Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
6.4 France Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Adrenoleukodystrophy Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Adrenoleukodystrophy Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Adrenoleukodystrophy Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
7.5 India Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Adrenoleukodystrophy Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Adrenoleukodystrophy Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Adrenoleukodystrophy Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Adrenoleukodystrophy Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Adrenoleukodystrophy Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Adrenoleukodystrophy Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Adrenoleukodystrophy Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Adrenoleukodystrophy Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Adrenoleukodystrophy Drugs Price by Type (2015-2020)
11 Global Adrenoleukodystrophy Drugs Market Segment by Application
11.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2015-2020)
11.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Adrenoleukodystrophy Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Adrenoleukodystrophy Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Adrenoleukodystrophy Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Adrenoleukodystrophy Drugs Market Forecast (2021-2025)
12.2.2 Europe Adrenoleukodystrophy Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Adrenoleukodystrophy Drugs Market Forecast (2021-2025)
12.2.4 South America Adrenoleukodystrophy Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Adrenoleukodystrophy Drugs Market Forecast (2021-2025)
12.3 Adrenoleukodystrophy Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Adrenoleukodystrophy Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Adrenoleukodystrophy Drugs Market Share Forecast by Type (2021-2025)
12.4 Adrenoleukodystrophy Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Adrenoleukodystrophy Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Adrenoleukodystrophy Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables

Table 1. Global Adrenoleukodystrophy Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Adrenoleukodystrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Adrenoleukodystrophy Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Applied Genetic Technologies Corp Basic Information, Manufacturing Base and Competitors
Table 8. Applied Genetic Technologies Corp Adrenoleukodystrophy Drugs Major Business
Table 9. Applied Genetic Technologies Corp Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 10. Applied Genetic Technologies Corp SWOT Analysis
Table 11. Applied Genetic Technologies Corp Adrenoleukodystrophy Drugs Product and Services
Table 12. Applied Genetic Technologies Corp Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Viking Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 14. Viking Therapeutics Inc Adrenoleukodystrophy Drugs Major Business
Table 15. Viking Therapeutics Inc Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 16. Viking Therapeutics Inc SWOT Analysis
Table 17. Viking Therapeutics Inc Adrenoleukodystrophy Drugs Product and Services
Table 18. Viking Therapeutics Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Minoryx Therapeutics sl Basic Information, Manufacturing Base and Competitors
Table 20. Minoryx Therapeutics sl Adrenoleukodystrophy Drugs Major Business
Table 21. Minoryx Therapeutics sl Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 22. Minoryx Therapeutics sl SWOT Analysis
Table 23. Minoryx Therapeutics sl Adrenoleukodystrophy Drugs Product and Services
Table 24. Minoryx Therapeutics sl Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Bluebird Bio Inc Basic Information, Manufacturing Base and Competitors
Table 26. Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Business
Table 27. Bluebird Bio Inc Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Bluebird Bio Inc SWOT Analysis
Table 29. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product and Services
Table 30. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. SOM Biotech SL Basic Information, Manufacturing Base and Competitors
Table 32. SOM Biotech SL Adrenoleukodystrophy Drugs Major Business
Table 33. SOM Biotech SL Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 34. SOM Biotech SL SWOT Analysis
Table 35. SOM Biotech SL Adrenoleukodystrophy Drugs Product and Services
Table 36. SOM Biotech SL Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. MedDay SA Basic Information, Manufacturing Base and Competitors
Table 38. MedDay SA Adrenoleukodystrophy Drugs Major Business
Table 39. MedDay SA Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 40. MedDay SA SWOT Analysis
Table 41. MedDay SA Adrenoleukodystrophy Drugs Product and Services
Table 42. MedDay SA Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. ReceptoPharm Inc Basic Information, Manufacturing Base and Competitors
Table 44. ReceptoPharm Inc Adrenoleukodystrophy Drugs Major Business
Table 45. ReceptoPharm Inc Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 46. ReceptoPharm Inc SWOT Analysis
Table 47. ReceptoPharm Inc Adrenoleukodystrophy Drugs Product and Services
Table 48. ReceptoPharm Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 50. Pfizer Inc Adrenoleukodystrophy Drugs Major Business
Table 51. Pfizer Inc Adrenoleukodystrophy Drugs Total Revenue (USD Million) (2018-2019)
Table 52. Pfizer Inc SWOT Analysis
Table 53. Pfizer Inc Adrenoleukodystrophy Drugs Product and Services
Table 54. Pfizer Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Global Adrenoleukodystrophy Drugs Sales by Manufacturer (2018-2019) (K Pcs)
Table 56. Global Adrenoleukodystrophy Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 57. Global Adrenoleukodystrophy Drugs Sales by Regions (2015-2020) (K Pcs)
Table 58. Global Adrenoleukodystrophy Drugs Sales Market Share by Regions (2015-2020)
Table 59. Global Adrenoleukodystrophy Drugs Revenue by Regions (2015-2020) (USD Million)
Table 60. North America Adrenoleukodystrophy Drugs Sales by Countries (2015-2020) (K Pcs)
Table 61. North America Adrenoleukodystrophy Drugs Sales Market Share by Countries (2015-2020)
Table 62. North America Adrenoleukodystrophy Drugs Revenue by Countries (2015-2020) (USD Million)
Table 63. North America Adrenoleukodystrophy Drugs Revenue Market Share by Countries (2015-2020)
Table 64. Europe Adrenoleukodystrophy Drugs Sales by Countries (2015-2020) (K Pcs)
Table 65. Europe Adrenoleukodystrophy Drugs Sales Market Share by Countries (2015-2020)
Table 66. Europe Adrenoleukodystrophy Drugs Revenue by Countries (2015-2020) (USD Million)
Table 67. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Regions (2015-2020) (K Pcs)
Table 68. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share by Regions (2015-2020)
Table 69. Asia-Pacific Adrenoleukodystrophy Drugs Revenue by Regions (2015-2020) (USD Million)
Table 70. South America Adrenoleukodystrophy Drugs Sales by Countries (2015-2020) (K Pcs)
Table 71. South America Adrenoleukodystrophy Drugs Sales Market Share by Countries (2015-2020)
Table 72. South America Adrenoleukodystrophy Drugs Revenue by Countries (2015-2020) (USD Million)
Table 73. South America Adrenoleukodystrophy Drugs Revenue Market Share by Countries (2015-2020)
Table 74. Middle East & Africa Adrenoleukodystrophy Drugs Sales by Countries (2015-2020) (K Pcs)
Table 75. Middle East & Africa Adrenoleukodystrophy Drugs Sales Market Share by Countries (2015-2020)
Table 76. Middle East & Africa Adrenoleukodystrophy Drugs Revenue by Countries (2015-2020) (USD Million)
Table 77. Middle East & Africa Adrenoleukodystrophy Drugs Revenue Market Share by Countries (2015-2020)
Table 78. Global Adrenoleukodystrophy Drugs Sales by Type (2015-2020) (K Pcs)
Table 79. Global Adrenoleukodystrophy Drugs Sales Share by Type (2015-2020)
Table 80. Global Adrenoleukodystrophy Drugs Revenue by Type (2015-2020) (USD Million)
Table 81. Global Adrenoleukodystrophy Drugs Revenue Share by Type (2015-2020)
Table 82. Global Adrenoleukodystrophy Drugs Sales by Application (2015-2020) (K Pcs)
Table 83. Global Adrenoleukodystrophy Drugs Sales Share by Application (2015-2020)
Table 84. Global Adrenoleukodystrophy Drugs Sales Forecast by Regions (2021-2025) (K Pcs)
Table 85. Global Adrenoleukodystrophy Drugs Market Share Forecast by Regions (2021-2025)
Table 86. Global Adrenoleukodystrophy Drugs Sales Forecast by Type (2021-2025) (K Pcs)
Table 87. Global Adrenoleukodystrophy Drugs Market Share Forecast by Type (2021-2025)
Table 88. Global Adrenoleukodystrophy Drugs Sales Forecast by Application (2021-2025)
Table 89. Global Adrenoleukodystrophy Drugs Market Share Forecast by Application (2021-2025)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Adrenoleukodystrophy Drugs Picture
Figure 2. Global Sales Market Share of Adrenoleukodystrophy Drugs by Type in 2019
Figure 3. Biotin Picture
Figure 4. DRX-065 Picture
Figure 5. DUOC-01 Picture
Figure 6. Lenti-D Picture
Figure 7. MIN-102 Picture
Figure 8. OP-101 Picture
Figure 9. Others Picture
Figure 10. Adrenoleukodystrophy Drugs Sales Market Share by Application in 2018
Figure 11. Children Picture
Figure 12. Adult Picture
Figure 13. Global Adrenoleukodystrophy Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Adrenoleukodystrophy Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturer in 2019
Figure 34. Global Adrenoleukodystrophy Drugs Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Adrenoleukodystrophy Drugs Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Adrenoleukodystrophy Drugs Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 39. Global Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Adrenoleukodystrophy Drugs Revenue Market Share by Regions (2015-2020)
Figure 41. Global Adrenoleukodystrophy Drugs Revenue Market Share by Regions in 2018
Figure 42. North America Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
Figure 43. Europe Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
Figure 45. South America Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020)
Figure 47. North America Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Adrenoleukodystrophy Drugs Sales Market Share by Countries (2015-2020)
Figure 49. North America Adrenoleukodystrophy Drugs Sales Market Share by Countries in 2018
Figure 50. North America Adrenoleukodystrophy Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Adrenoleukodystrophy Drugs Revenue Market Share by Countries in 2018
Figure 52. United States Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Canada Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Mexico Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Europe Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Countries in 2019
Figure 58. Germany Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. UK Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. France Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Italy Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Asia-Pacific Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Adrenoleukodystrophy Drugs Revenue Market Share by Regions 2019
Figure 66. China Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Korea Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. India Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Southeast Asia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. South America Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Adrenoleukodystrophy Drugs Sales Market Share by Countries in 2019
Figure 73. South America Adrenoleukodystrophy Drugs Revenue Market Share by Countries in 2019
Figure 74. Brazil Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Argentina Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Middle East and Africa Adrenoleukodystrophy Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Adrenoleukodystrophy Drugs Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Adrenoleukodystrophy Drugs Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Egypt Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Turkey Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. South Africa Adrenoleukodystrophy Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Global Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2025) (K Pcs)
Figure 85. Global Adrenoleukodystrophy Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Adrenoleukodystrophy Drugs Market Forecast (2021-2025) (K Pcs)
Figure 87. Europe Sales Adrenoleukodystrophy Drugs Market Forecast (2021-2025) (K Pcs)
Figure 88. Asia-Pacific Sales Adrenoleukodystrophy Drugs Market Forecast (2021-2025) (K Pcs)
Figure 89. South America Sales Adrenoleukodystrophy Drugs Market Forecast (2021-2025) (K Pcs)
Figure 90. Middle East & Africa Sales Adrenoleukodystrophy Drugs Market Forecast (2021-2025) (K Pcs)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel